Market revenue in 2023 | USD 7.0 million |
Market revenue in 2030 | USD 9.9 million |
Growth rate | 5.1% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III |
Key market players worldwide | Almac Group, Catalent Inc, Waldencast PLC Class A, PCI Technology, Sharp Corp, Thermo Fisher Scientific Inc, PAREXEL, Marken, KLIFO, BioCair |
Phase iii was the largest segment with a revenue share of 54.29% in 2023. Horizon Databook has segmented the Saudi Arabia clinical trial supplies market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.
Availability of low-cost clinical resources, presence of qualified investigators, and ease in patient recruitment are some of the major factors boosting the growth of clinical trial supplies market in this country.
Advancements in technology, rise in disease prevalence, and quicker regulatory approval as compared to countries such as China, India, and Brazil are expected to further fuel growth of clinical trial supplies market in the region.
Presence of key players such as PAREXEL International Corporation and increase in the number of clinical trials are among factors further expected to boost competition and expand the market for clinical trial supplies.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account